Given the high mutant frequency of BRAF in THCA and SKCM, and KRAS in PAAD and COREAD, such 4 cancer types were significantly enriched in C1 pharmacological subtype of MEK1/2 inhibitor Refametinib (THCA, p = 1.90e-2; SKCM, p = 1.23e-14; PAAD, p = 3.01e-4; COREAD, p = 3.84e-5; Hypergeometric Distribution Test) (Supplementary Table S2). Here, BRAF is linked to cancer.